Mirtazapine augmentation in the treatment of refractory depression.
- 15 January 1999
- journal article
- clinical trial
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 60 (1) , 45-49
- https://doi.org/10.4088/jcp.v60n0110
Abstract
Pharmacotherapeutic strategies that target specific actions at multiple neuronal receptors or cellular components may offer a superior approach for treatment of refractory depression. Mirtazapine is a novel antidepressant which has a mechanism that involves the enhancement of noradrenergic and serotonergic neurotransmission via blockade of alpha2-adrenergic autoreceptors and heteroreceptors without activity at the serotonin transporter. Mirtazapine is thus a compelling candidate for augmentation treatment in patients who fail to achieve adequate response with other antidepressant medications.Keywords
This publication has 0 references indexed in Scilit: